Public interest group challenges ‘unmerited’ Gilead patents
26-10-2017
Indian Pharmaceutical Alliance drops Sovaldi opposition
16-09-2015
JENG_NIAMWHAN / Shutterstock.com
Gilead Sciences is facing a challenge to its attempt to obtain a patent for its hepatitis C drug Sovaldi (sofosbuvir) in certain Asian, Latin American and European countries.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Gilead Sciences; Sovaldi; Initiative for Medicines, Access and Knowledge; patent application; Hepatitis C
